Lesion in Body Region Clinical Trial
Official title:
Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)
The trial aims at evaluating the efficacy and the safety of gadopiclenol for body Magnetic resonance Imaging (MRI)
The purpose of this trial is to evaluate a new gadolinium-based contrast agent (GBCA) gadopiclenol in terms of lesion visualization in patients referred for contrast-enhanced MRI of body regions. This is a prospective, international, multi-center, randomized, double-blind, controlled and cross-over trial. This trial will be conducted in approximately 50 centers worldwide. During the course of the trial, two MRIs will be obtained from each patient: one with gadopiclenol and one with gadobutrol. MRI evaluations will be assessed by independent off-site blinded readers. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06010173 -
Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children
|
Phase 3 |